Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Both doses late Clear all
Completed No phase listed Observational Accepts healthy volunteers

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

NCT02280642
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

PT150 Drug for Use in Alcohol Use Disorder

NCT06712602
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
alcohol, Stress-Induction, PT150
Drug · Behavioral
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Withdrawn Phase 2 Interventional

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

NCT01561482
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Metformin, Simvastatin
Drug
Lead sponsor
Nicholas Mitsiades
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 9, 2026, 11:15 AM EDT
Completed No phase listed Observational

GlowCaps Adherence Randomized Control Trial

NCT01756001
View directory record Official record
Conditions
Medical Adherence
Interventions
GlowCap, Daily email, text message, or phone call reminders, Paid for adherence
Device · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 84 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 9, 2026, 11:15 AM EDT
Withdrawn Phase 4 Interventional

Timing of VTE Prophylaxis in TBI

NCT03081169
View directory record Official record
Conditions
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Interventions
Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EXPLORER PET/CT in Healthy Volunteers

NCT04110743
View directory record Official record
Conditions
Healthy
Interventions
EXPLORER PET/CT
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Completed No phase listed Observational

The Reproducibility and Consistency of Instrument-assisted Soft Tissue Manipulation

NCT04923633
View directory record Official record
Conditions
Massage
Interventions
Quantifiable Soft Tissue Manipulation (QSTM)
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

NCT03073525
View directory record Official record
Conditions
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Vigil, Atezolizumab
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
View directory record Official record
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Trial of an Investigational Small Pox Medication

NCT00728689
View directory record Official record
Conditions
Orthopoxviral Disease, Smallpox, Monkey Pox
Interventions
ST-246 Days 1 - 3, ST-246 Days 11 - 13
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional Results available

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

NCT01039376
View directory record Official record
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Observation
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
43
States / cities
Gilbert, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

NCT00536120
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab Treatment For Type 1 ROP

NCT04634578
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

NCT05471076
View directory record Official record
Conditions
HIV-1-infection
Interventions
426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg, Placebo, BG505
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Not applicable Interventional Results available

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Early ibuprofen, Late ibuprofen expectant group (placebo)
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 14 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

NCT02280356
View directory record Official record
Conditions
Prostate Cancer
Interventions
external beam radiation therapy, brachytherapy, questionnaires
Radiation · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Withdrawn Phase 1 Interventional

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

NCT05079451
View directory record Official record
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
CMC-544 (Inotuzumab Ozogamycin), Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 9, 2026, 11:15 AM EDT